Top

Supportive Care in Cancer

Published in:

01-11-2016 | Original Article

Efficacy benefit of an NK₁ receptor antagonist (NK₁RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK₁ RA, netupitant, and palonosetron) and aprepitant regimens

Authors: Karin Jordan, Richard Gralla, Giada Rizzi, Kimia Kashef

Published in: Supportive Care in Cancer | Issue 11/2016

Abstract

Purpose

Antiemetic guideline recommendations are inconsistent as to whether a neurokinin-1 receptor antagonist (NK₁ RA) should be administered with a 5-hydroxytryptamine-3 (5HT₃) RA + dexamethasone (DEX) in patients receiving carboplatin. Patients receiving cisplatin routinely receive an NK₁ RA-containing regimen with a resulting 14–22 % benefit in no emesis rates over a 5-HT₃ RA/DEX control. Recent studies suggest a similar benefit in patients receiving carboplatin. NEPA is the first fixed antiemetic combination agent and comprises the highly selective NK₁ RA, netupitant, and pharmacologically distinct 5-HT₃ RA, palonosetron (PALO). This paper presents the efficacy of NEPA in the subset of patients receiving carboplatin in a phase 3 trial (NCT01376297), in the context of aprepitant (APR) data in the carboplatin setting.

Methods

One hundred ninety-six patients (47 % of all study patients: n = 145 NEPA + DEX; n = 51 APR + PALO + DEX) received carboplatin in a multinational, double-blind, randomized phase 3 study. Complete response (CR: no emesis/rescue) and no significant nausea (NSN: score ≤25 on 100 mm visual analog scale) rates were calculated.

Results

Cycle 1–4 overall (0–120 h) CR rates were similar for NEPA (80, 91, 92, and 93 %) and APR (82, 88, 88, and 90 %). Overall NSN rates were also similar (NEPA 84–96 %; APR 82–90 %).

Conclusions

Response rates for NEPA and APR regimens were similar and consistent with prior studies evaluating the contribution of adding NK₁ RAs in patients receiving carboplatin. Considering such evidence, guideline groups/practitioners should consider giving a NK₁ RA antiemetic triplet in patients receiving carboplatin.

Hesketh PJ, Kris MG, Grunberg SM, et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109PubMed

Hesketh PJ, Bohlke K, Lyman GH, et al. (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381–386CrossRefPubMed

MASCC/ESMO Antiemetic Guideline (2016). Available from: http://www.mascc.org/assets/Guidelines-tools/mascc_antiemetic_guidelines_english_2016_v.1.1.pdf

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2016). Antiemesis Version 2. Available from: http://www.nccn.org

Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4(3):191–196PubMed

Cubeddu LX, Hoffmann I, Guenmayor NT, Finn AL (1990) Efficacy of ondansetron and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810–816CrossRefPubMed

Gershenson DM, Wharton JT, Herson J, et al. (1981) Single-agent cisplatinum therapy for advanced ovarian cancer. Obstet Gynecol 58:487PubMed

Grunberg SM, Osoba D, Hesketh PJ, et al. (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84CrossRefPubMed

Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV). Ann Oncol 26(6):1081–1090CrossRefPubMed

10.

Du Bois A, Vach W, Thomssen C, et al. (1994) Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. Acta Oncol 33(5):531–535CrossRefPubMed

11.

PARAPLATIN® (carboplatin aqueous solution) INJECTION [package insert]. Bristol-Myers Squibb Company, Princeton, NJ 08543 USA. Revised Apr 2015

12.

Swenerton K, Jeffrey J, Stuart G, et al. (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 10:718–726PubMed

13.

Hannigan EV, Green S, Alberts DS, et al. (1993) Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50(2):2–9CrossRefPubMed

14.

Tanioka M, Kitao A, Matsumoto K, et al. (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859–865CrossRefPubMedPubMedCentral

15.

Ito Y, Karayama M, Inui N, et al. (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259–264CrossRefPubMed

16.

Yahata H, Kobayashi H, Sonoda K, et al. (2015) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. doi:10.1007/s10147-015-0928-y PubMed

17.

Gralla R, Rapoport B, Brown C, et al. (2009) Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers. Eur J Cancer 7(3):23–24 (abstr 57LBA)CrossRef

18.

Rapoport BL, Jordan K, Boice JA, et al. (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMed

19.

Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing chemotherapy induced nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer doi:10.1002/cncr.30054 PubMed

20.

Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT₃ and NK₁ receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37CrossRefPubMed

21.

Stathis M, Pietra C, Rojas C, Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689(1–3):25–30CrossRefPubMed

22.

Morganroth J, Parisi S, Moresino C, Thorn M, Cullen MT (2009) High dose palonosetron does not alter ECG parameters, including QTc interval in healthy subjects: results of a dose response, double blind, randomized parallel E14 study of palonosetron vs moxifloxacin or placebo. Eur J Cancer 5(4):158–159 (abstr 1156)CrossRef

23.

Gonullu G, Demircan S, Demirag MK, et al. (2012) Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 20:1435–1439CrossRefPubMed

24.

Yavas C, Dogan U, Yavas G, et al. (2012) Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer 20:2343–2347CrossRefPubMed

25.

Dogan U, Yavas G, Tekinalp M, et al. (2012) Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur Rev Med Pharmacol Sci 16:462–468PubMed

26.

Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30–38CrossRefPubMed

27.

Gralla R, Lichinitser M, Van Der Vegt S, et al. (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577CrossRefPubMed

28.

Saito M, Aogi K, Sekine I, et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial. Lancet Oncol 10(2):115–124CrossRefPubMed

29.

Aapro MS, Grunberg SM, Manikhas GM, et al. (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449CrossRefPubMed

30.

Thomas AG, Stathis M, Rojas C, Slusher BS (2014) Netupitant and palonosetron trigger NK₁ receptor internalization in NG108-15 cells. Exp Brain Res 232(8):2637–2644CrossRefPubMedPubMedCentral

31.

Hesketh PJ, Rossi G, Rizzi G, et al. (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346CrossRefPubMedPubMedCentral

32.

Aapro M, Rugo H, Rossi G, et al. (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRefPubMedPubMedCentral

33.

Gralla RJ, Bosnjak SM, Hontsa A, et al. (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339CrossRefPubMedPubMedCentral

34.

Hesketh PJ, Grunberg S, Gralla R, et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 study group. J Clin Oncol 21:4112–4119CrossRefPubMed

35.

Poli-Bigelli S, Rodrigues-Peretra J, Carides A, et al. (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098CrossRefPubMed

36.

Schmoll HJ, Aapro M, Poli-Bigelli S, et al. (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000–1006CrossRefPubMed

Title: Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens
Authors: Karin Jordan
Richard Gralla
Giada Rizzi
Kimia Kashef
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3304-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2016

Predicting trajectories of behavioral adjustment in children diagnosed with acute lymphoblastic leukemia

Post-intensive care unit syndrome in gynecologic oncology patients

The perceptions of Australian oncologists about cognitive changes in cancer survivors

Predisposing factors for postoperative nausea and vomiting in gynecologic tumor patients

Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients

Prevalence of unmet needs and correlated factors in advanced-stage cancer patients receiving rehabilitation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer